Can, CananAkdeniz, NadiyeKömek, HalilGündoğan, CihanUrakçı, ZuhatIşıkdogan, Abdurrahman2023-03-032023-03-032022Can, C., Akdeniz, N., Kömek, H., Gündoğan, C., Urakçı, Z. ve Işıkdogan, A. (2022). The prognostic role of baseline F-18-FDG PET/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapy. Revista Espanola de Medicina Nuclear E Imagen Molecular, 41(1), 3-10.2253-654Xhttps://hdl.handle.net/11468/11311Objective: This study aimed to determine the prognostic role of baseline maximum standardized uptake value (SUVmax) obtained by pretreatment PET/CT and the change in SUVmax ( ASUVmax [90]) in patients with axillary lymph node -positive breast cancer receiving neoadjuvant chemotherapy (NAC). Methods: One hundred and eighty patients with baseline SUVmax and 121 patients with SUVmax measurement after treatment were evaluated in the study. The baseline SUVmax value of the breast (SUVmaxBI) and axilla (SUVmaxAl) and the change in the SUVmax of the breast (ASUVmaxp,) and axilla (ASUVmaxA) were measured. The optimal cut-off value of SUVmax and ASUVmax were determined by ROC curve analysis. Disease-free survival (DFS) and overall survival (OS) were calculated using Kaplan -Meier curves. Results: \SUVmax5, pCRB, pCRA, and pCR parameters were found to be associated with relapse (P<.001, P=.033, P=.016, and P=.013, respectively). ASUVmaxB and SUVmaxAl were associated with mortality (P=.001 and P=.006, respectively). Multiple Cox regression analyses revealed that \SUVmax5 value was an independent prognostic factor for relapse and mortality (P=.013 and P=.010, respectively). Conclusion: The results showed that ASUVmax5 was an independent prognostic factor for relapse and mortality in patients with axillary lymph node -positive breast cancer who received NAC. 0 2021 Sociedad Espanola de Medicina Nuclear e lmagen Molecular. Published by Elsevier Espana, S.L.U. All rights reserved.eninfo:eu-repo/semantics/closedAccessBreast cancer(18)FDG PET/CTNeoadjuvant chemotherapySUVmax changePrediction responsePrognosisArticle411310WOS:00074142400000234991833Q4